SecurityTST / TheStreet, Inc. (88368Q103)
Interim CEOKRAMER LAWRENCE S
IndustryNewspapers: Publishing, or Publishing and Printing
Institutional Owners48
Institutional Shares24,741,876 - 50.30%
Common Shares Outstanding49,191,024 shares (as of 2018-03-31)
Institutional Value$ 42,958,000 USD

Institutional Stock Ownership and Shareholders()

TheStreet, Inc. (NASDAQ:TST) has 48 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24,741,876 shares. Largest shareholders include Technology Crossover Management VI, L.L.C., HighTower Advisors, LLC, Cannell Capital Llc, Renaissance Technologies LLC, Punch & Associates Investment Management, Inc., Pax World Management Llc, BlackRock Institutional Trust Company, N.A., Vanguard Group Inc, BlackRock Inc., and EAM Investors, LLC.
TheStreet, Inc. (NASDAQ:TST) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-11 13F-HR KNOTT DAVID M 100,600 90,600 -9.94 146 162 10.96
2017-02-10 13F-HR BlackRock Investment Management, LLC 5,877 5,877 0.00 6 5 -16.67
2018-05-09 13F-HR BlackRock Inc. 1,314,482 1,299,197 -1.16 1,906 2,326 22.04
2018-05-15 13F-HR Cruiser Capital Advisors, Llc 122,426 122,426 0.00 178 219 23.03
2018-05-09 13F-HR NORTHERN TRUST CORP 62,188 55,131 -11.35 90 99 10.00
2018-05-15 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 146,815 146,815 0.00 213 263 23.47
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 12,700 9,701 -23.61 18 17 -5.56
2018-05-14 13F-HR Renaissance Technologies LLC 2,316,393 2,671,900 15.35 3,359 4,783 42.39
2018-05-15 13F-HR DEUTSCHE BANK AG\ 185,036 310,363 67.73 268 555 107.09
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 13,606 13,072 -3.92 20 23 15.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 79,200 79,200 0.00 115 142 23.48
2018-05-14 13F-HR CANNELL CAPITAL LLC 2,706,747 2,794,999 3.26 3,925 5,003 27.46
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 1,361,991 1,361,991 0.00 1,498 1,158 -22.70
2018-05-14 13F-HR WHITE PINE CAPITAL LLC 30,078 54
2018-05-10 13F-HR JP Morgan Chase & Co 13,961 35,860 156.86 20 64 220.00
2018-05-14 13F-HR PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. 1,678,569 1,678,569 0.00 2,434 3,005 23.46
2018-05-15 13F-HR STATE STREET CORP 13,500 13,500 0.00 19 24 26.32
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 161,947 290
2018-05-14 13F-HR EAM Investors, LLC 366,954 657
2018-05-09 13F-HR IFP Advisors, Inc 0 115 0 0
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 0 76,622 0 137
2018-05-14 13F-HR MORGAN STANLEY 148 148 0.00 0 0
2018-05-01 13F-HR Joel Isaacson & Co., LLC 51,119 51,119 0.00 74 92 24.32
2018-05-14 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 16,585 30
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 97,860 97,860 0.00 141 175 24.11
2018-05-14 13F-HR Virtu Financial LLC 70,744 127
2018-06-04 13F-HR Eam Global Investors Llc 11,683 21
2018-05-11 13F-HR CITIGROUP INC 4,000 4,000 0.00 6 7 16.67
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 758 4,142 446.44 1 7 600.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 22,507 33,733 49.88 33 60 81.82
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,654 0 -100.00 2 0 -100.00
2018-05-15 13F-HR HighTower Advisors, LLC 3,100,465 3,261,936 5.21 4,495 5,839 29.90
2018-05-15 13F-HR A.R.T. Advisors, LLC 19,272 0 -100.00 27 0 -100.00
2018-05-10 13F-HR Spark Investment Management LLC 26,600 91,600 244.36 38 163 328.95
2018-07-17 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 185,849 185,849 0.00 333 405 21.62
2017-02-10 13F-HR BlackRock Advisors LLC 16,585 16,585 0.00 18 14 -22.22
2018-05-15 13F-HR Bank of New York Mellon Corp 32,685 51,902 58.79 47 94 100.00
2018-05-15 13F-HR UBS Group AG 4,000 4,000 0.00 6 7 16.67
2018-05-09 13F-HR Teton Advisors, Inc. 70,000 70,000 0.00 102 125 22.55
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 23 23 0.00 0 0
2018-05-15 13F-HR VANGUARD GROUP INC 797,944 1,353,913 69.68 1,157 2,424 109.51
2018-05-11 13F-HR CITADEL ADVISORS LLC 33,733 60
2018-04-20 13F-HR FIRST MANHATTAN CO 3,583 6
2018-05-11 13F-HR SEI INVESTMENTS CO 2,000 4
2018-05-04 13F-HR MISSION WEALTH MANAGEMENT, LLC 10,000 0 -100.00 15 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 348,600 298,600 -14.34 505 534 5.74
2018-05-14 13F-HR PAX WORLD MANAGEMENT LLC 1,471,653 1,471,653 0.00 2,134 2,634 23.43
2018-06-28 13F-HR/A BROWN ADVISORY INC 141,646 141,646 0.00 205 254 23.90
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 0 32,881 0 59
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 150 0
2018-05-14 13F-HR Technology Crossover Management VI, L.L.C. 6,000,000 6,000,000 0.00 8,700 10,740 23.45
2018-05-11 13F-HR Bandera Partners LLC 469,178 0 -100.00 680 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 103,755 106,891 3.02 114 91 -20.18

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

8h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Related News Stories

Ovid's De-Risked Drug Primed For Phase II Readout

2018-06-15 seekingalpha
I discuss the background science, including a "failed" phase 3 of this drug already done by Merck. (16-1)

TURN: A 180-Degree Turnaround Story With A Margin Of Safety

2018-05-31 seekingalpha
180 Degree Capital's stock trades at a 34.59% discount to Net Asset Value ((NAV)) with no debt. (40-1)

TheStreet's (TST) CEO David Callaway on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good day, and welcome to the First Quarter 2018 Financial Results. Today's call is being recorded. I would now like to hand the call over to Mr. Eric Lundberg, Chief Financial Officer. Please go ahead, sir. (32-0)

5 Technology Stocks Poised to Surpass Earnings Estimates

2018-05-07 zacks
The first quarter earnings season is approaching its end with 409 S&P 500 members having already reported their quarterly results, as of May 4. Notably, the Technology sector is one of the top performers this earnings season, despite the many hurdles that it faced during the quarter. The Technology Select Sector SPDR ETF (“XLK”) returned 5.8% in the year-to-date period against the S&P 500’s decline of 0. (67-0)

Can Higher Business Sales Aid CenturyLink (CTL) Q1 Earnings?

2018-05-07 zacks
CenturyLink, Inc. (CTL - Free Report) is scheduled to report first-quarter 2018 financial results after the closing bell on May 9. The company is likely to report higher consolidated revenues on the back of healthy growth dynamics. Whether this could result into an earnings beat for the quarter remains to be seen. Factors at Play During the first quarter, CenturyLink received approval from the U.S. (85-0)

CUSIP: 88368Q103